Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Cited by (530)

Items 101–200 of 530

1. Current and future trends in the lipid lowering therapy
   Bogusław Okopień, Łukasz Bułdak, Aleksandra Bołdys · 2016 · Pharmacological Reports
2. Advances in biological therapies for dyslipidemias and atherosclerosis
   Eftaxia-Konstantina Valanti, Katerina Dalakoura-Karagkouni, Gerasimos Siasos, Dimitris Kardassis, Aristides G. Eliopoulos, Despina Sanoudou · 2020 · Metabolism
3. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK 9, lipoprotein(a) and apolipoprotein C‐ III
   Moumita Ghosh Laskar, Mats Eriksson, Mats J. Rudling, Bo Angelin · 2017 · Journal of Internal Medicine
4. Lipid Lowering Drugs: Present Status and Future Developments
   Ruscica, Massimiliano, Ferri, Nicola, Santos, Raul D., Sirtori, Cesare R., Corsini, Alberto · 2021 · Current Atherosclerosis Reports
5. Novel emerging therapies in atherosclerosis targeting lipid metabolism
   Manasvi Gupta, Colin Blumenthal, Subhankar Chatterjee, Dhrubajyoti Bandyopadhyay, Vardhmaan Jain, Carl J. Lavie, Salim S. Virani, Kausik Kumar Ray, Wilbert S. Aronow, Raktim K. Ghosh · 2020 · Expert Opinion on Investigational Drugs
6. The Role of Emerging Risk Factors in Cardiovascular Outcomes
   Ben Lacey, William Guy Herrington, David Preiss, Sarah Lewington, Jane Armitage · 2017 · Current Atherosclerosis Reports
7. Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
   Werner J. Geldenhuys, Lin Li, Altaf S. Darvesh, Prabodh Sadana · 2016 · Drug Discovery Today
8. New Therapies for Lowering Triglyceride-Rich Lipoproteins
   Robert S. Rosenson, Aleesha Shaik, Wen‐Liang Song · 2021 · Journal of the American College of Cardiology
9. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
   Chris J. Packard, Angela Pirillo, Sotirios Tsimikas, Brian A. Ference, Alberico Luigi Catapano · 2023 · Cardiovascular Research
10. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
    Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos E. Kypreos, Theodosios D. Filippatos · 2021 · Current Atherosclerosis Reports
11. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text
    Kolovou, Genovefa D., Watts, Gerald F., Mikhailidis, Dimitri P., Pérez-Martínez, Pablo, Mora, Samia, Bilianou, Helen, Panotopoulos, George, Katsiki, Niki, Ooi, Teik C., Lopez-Miranda, José et al. · 2019 · Current Vascular Pharmacology
12. RNA-targeted therapeutics for lipid disorders
    Sotirios Tsimikas · 2018 · Current Opinion in Lipidology
13. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
    Ramms, Bastian, Patel, Sohan, Nora, Chelsea, Pessentheiner, Ariane R., Chang, Max W., Green, Courtney R., Golden, Gregory J., Secrest, Patrick, Krauss, Ronald M., Metallo, Christian M. et al. · 2019 · Journal of Lipid Research
14. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
    Clarice Gareri, Alberto Polimeni, Salvatore A. Giordano, Laura Tammè, Antonio Curcio, Ciro Indolfi · 2022 · Journal of Clinical Medicine
15. New Era of Lipid-Lowering Drugs
    Philip J. Barter, Kerry‐Anne Rye · 2016 · Pharmacological Reviews
16. Antisense Oligonucleotide (AS‐ODN) Technology: Principle, Mechanism and Challenges
    Seyed Mohammad Gheibi Hayat, Khadijeh Jamialahmadi · 2020 · Biotechnology and Applied Biochemistry
17. Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes
    George Hindy, Peter Dornbos, Mark D. Chaffin, Dajiang J. Liu, Minxian Wang, Margaret Sunitha Selvaraj, David Zhang, Joseph Park, Carlos Alberto Aguilar-Salinas, Lucinda Fulton et al. · 2021 · The American Journal of Human Genetics
18. Hypertriglyceridemia and Cardiovascular Diseases: Revisited
    Seung Hwan Han, Stephen James Nicholls, Ichiro Sakuma, Dong Hui Zhao, Kwang Kon Koh · 2016 · Korean Circulation Journal
19. Diabetic dyslipidaemia
    Soran, Handrean, Schofield, Jonathan D., Adam, Safwaan, Durrington, Paul N. · 2016 · Current Opinion in Lipidology
20. PPAR-α agonists are still on the rise: an update on clinical and experimental findings
    Nicola Ferri, Alberto Corsini, Cesare Riccardo Sirtori, Massimiliano Ruscica · 2017 · Expert Opinion on Investigational Drugs
21. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics
    Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Sihlbom, C., Thorsell, A., Zhou, H. et al. · 2019 · Journal of Internal Medicine
22. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
    Rocha, Natalia A., East, Cara, Zhang, Jun, McCullough, Peter A. · 2017 · Current Atherosclerosis Reports
23. Target Populations for Novel Triglyceride-Lowering Therapies
    Nordestgaard, Ask T., Tybjærg-Hansen, Anne, Mansbach, Hank, Kersten, Sander, Nordestgaard, Børge G., Rosenson, Robert S. · 2025 · Journal of the American College of Cardiology
24. Apolipoprotein C-II: the re-emergence of a forgotten factor
    Anna T Wolska, Mart Reimund, Alan Thomas Remaley · 2020 · Current Opinion in Lipidology
25. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
    Mengdie Luo, Daoquan Peng · 2016 · Lipids in Health and Disease
26. Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
    Yehuda Handelsman, Michael David Shapiro · 2016 · Endocrine Practice
27. Update on the laboratory investigation of dyslipidemias
    Ramasamy, I. · 2018 · Clinica Chimica Acta
28. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia
    Ewa Karwatowska‐Prokopczuk, Jean‐Claude Tardif, Daniel Gaudet, Christie Mitchell Ballantyne, Michael David Shapiro, Patrick M. Moriarty, Seth J. Baum, Eric St Amour, Veronica J. Alexander, Shuting Xia et al. · 2022 · Journal of clinical lipidology
29. High-density lipoproteins (HDL): Novel function and therapeutic applications
    Maryam Darabi, Anatol Kontush · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
30. Current Options and Future Perspectives in the Treatment of Dyslipidemia
    Saverio Muscoli, Mihaela Ifrim, Massimo Russo, Francesco Candido, Angela Sanseviero, Marialucia Milite, Marco Di Luozzo, Massimo Marchei, Giuseppe Sangiorgi · 2022 · Journal of Clinical Medicine
31. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides
    Hussein N. Yassine, Olgica Trenchevska, Ambika Ramrakhiani, Aarushi Parekh, Juraj Koška, Ryan W. Walker, Dean D. Billheimer, Peter D. Reaven, Frances T. Yen, Randall W. Nelson et al. · 2015 · PLoS ONE
32. Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
    Hayato Tada, Atsushi Nohara, Masa‐aki Kawashiri · 2018 · Nutrients
33. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
    Erin S. Morgan, Li-Jung Tai, Nguyen C. Pham, Julia K. Overman, Lynnetta M. Watts, Anne V. Smith, Shiangtung W. Jung, Martin Gajdošík, Martin Krššák, Michael Krebs et al. · 2019 · Diabetes Care
34. Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models
    Debapriya Basu, Karin Bornfeldt · 2020 · Frontiers in Endocrinology
35. Hypertriglyceridemia
    Alan Chait · 2022 · Endocrinology and Metabolism Clinics of North America
36. Serum Levels of Apolipoproteins and Incident Type 2 Diabetes: A Prospective Cohort Study
    Adela Brahimaj, Symen Ligthart, M. Arfan Ikram, Albert Hofman D, Oscar H. Franco, Eric J.G. Sijbrands, Maryam Kavousi, Abbas Dehghan · 2016 · Diabetes Care
37. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity
    Evangelia Zvintzou, Marie Lhomme, Stella Chasapi, Serafoula Filou, Vassilis Theodoropoulos, Eva Xapapadaki, Anatol Kontush, Georgios A. Spyroulias, Constantinos C. Tellis, Alexandros D. Tselepis et al. · 2017 · Journal of Lipid Research
38. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
    Nicholas Chew, Bryan Chong, Cheng Han Ng, Gwyneth Kong, Yip Han Chin, Wang Xiao, Chang Jie Mick Lee, Yock Young Dan, Mark Dhinesh Muthiah, Roger Foo · 2022 · Frontiers in Genetics
39. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia
    Thomas A Prohaska, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, Joseph A. Tami, Shuting Xia, Joseph Lee Witztum, Sotirios Tsimikas · 2023 · Journal of clinical lipidology
40. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
    Amirhossein Sahebkar, Luis E. Simental‐Mendía, Dimitri P. Mikhailidis, Matteo Pirro, Maciej Banach, Cesare Riccardo Sirtori, Željko Reiner · 2018 · Annals of Medicine
41. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study
    Ching‐Lung Cheung, K. C. B. Tan, Philip Chun-Ming Au, Gloria Hoi‐Yee Li, Bernard M.Y. Cheung · 2019 · EBioMedicine
42. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
    Kettunen, Johannes, Holmes, Michael V., Allara, Elias, Anufrieva, Olga, Ohukainen, Pauli, Oliver-Williams, Clare, Wang, Qin, Tillin, Therese, Hughes, Alun D., Kähönen, Mika et al. · 2019 · PLOS Biology
43. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study
    Riyaz S. Patel, Laura Pasea, Handrean Soran, Paul Downie, Richard Jones, Aroon Dinesh Hingorani, Dermot Neely, Spiros Denaxas, Harry Hemingway · 2022 · Cardiovascular Diabetology
44. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets
    Vincenza Barresi, Camillo Musmeci, Alessandro Rinaldi, D. F. Condorelli · 2022 · International Journal of Molecular Sciences
45. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
    Chen, Jingfei, Fang, Zhenfei, Luo, Qin, Wang, Xiao, Warda, Mohamad, Das, Avash, Oldoni, Federico, Luo, Fei · 2024 · Lipids in Health and Disease
46. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
    L. M. Strilchuk, Federica Fogacci, Arrigo F.G. Cicero · 2019 · Expert Opinion on Drug Safety
47. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects
    Björnson, E., Packard, C.J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J. et al. · 2020 · Journal of Internal Medicine
48. Extreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence
    Chyzhyk, Vadzim, Kozmic, Sarah, Brown, Alan S., Hudgins, Lisa C., Starc, Thomas J., Davila, Ashley Deleigh, Blevins, Thomas C., Diffenderfer, Margaret R., He, Lihong, Geller, Andrew S. et al. · 2019 · Journal of Clinical Lipidology
49. Effect of Exceptional Parental Longevity and Lifestyle Factors on Prevalence of Cardiovascular Disease in Offspring
    Sriram Gubbi, Elianna Schwartz, Jill P. Crandall, Joe Verghese, Roee Holtzer, Gil Atzmon, Rebecca Braunstein, Nir Barzilai, Sofiya Milman · 2017 · The American Journal of Cardiology
50. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome
    Rabia Chaudhry, Adie Viljoen, Anthony S. Wierzbicki · 2018 · Expert Review of Clinical Pharmacology
51. Apolipoprotein C3: form begets function
    Karin Bornfeldt · 2023 · Journal of Lipid Research
52. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis
    Vadzim Chyzhyk, Alan S. Brown · 2019 · Trends in Cardiovascular Medicine
53. Vaccination in Atherosclerosis
    Felix Sebastian Nettersheim, Lauren De Vore, Holger Winkels · 2020 · Cells
54. Novel therapeutics in hypertriglyceridemia
    Gryn, Steven E., Hegele, Robert A. · 2015 · Current Opinion in Lipidology
55. ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease
    Helkkula, Pyry, Kiiskinen, Tuomo, Havulinna, Aki S., Karjalainen, Juha, Koskinen, Seppo, Salomaa, Veikko, Daly, Mark J., Palotie, Aarno, Surakka, Ida, Ripatti, Samuli et al. · 2021 · PLOS Genetics
56. The Promise and Challenge of Therapeutic MicroRNA Silencing in Diabetes and Metabolic Diseases
    Praveen Sethupathy · 2016 · Current Diabetes Reports
57. RNA Therapeutics: How Far Have We Gone?
    Maria Francisca Coutinho, Liliana Matos, Juliana Inês Santos, Sandra Alves · 2019 · Advances in experimental medicine and biology
58. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
    Daniel Gaudet, Jean‐Philippe Drouin‐Chartier, Patrick Couture · 2017 · Canadian Journal of Cardiology
59. The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
    Jaana Hartiala, William S. Schwartzman, Julian Gabbay, Anatole Ghazalpour, Brian J. Bennett, Hooman Allayee · 2017 · Current Atherosclerosis Reports
60. DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes
    Connor A. Emdin, Amit V. Khera, Krishna G. Aragam, Mary E. Haas, Mark D. Chaffin, Derek M. Klarin, Pradeep Natarajan, Alexander G. Bick, Seyedeh Maryam Zekavat, Akihiro Nomura et al. · 2018 · Diabetes
61. Nucleic Acid–Based Therapies for Atherosclerosis
    Petri I. Mäkinen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala · 2020 · Current Atherosclerosis Reports
62. Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease
    Yating Wang, Li Shen, Danyan Xu · 2018 · Clinical Cardiology
63. Novel Therapeutic Targets for Managing Dyslipidemia
    Vasanth Sathiyakumar, Karan Kapoor, Steven Richard Jones, Maciej Banach, Seth Shay Martin, Peter Paul Toth · 2018 · Trends in Pharmacological Sciences
64. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis
    Romain Capoulade, Michael Torzewski, Manuel Mayr, Kwan‐Leung Chan, Patrick Mathieu, Yohan Bossé, Jean Gaston Dumesnil, James W. Tam, Koon Kang Teo, Sean Anthony Burnap et al. · 2020 · Heart
65. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross‐sectional study from a regional diabetes cohort
    Tsutomu Hirano, Noriyuki Satoh, Rieko Kodera, Takeshi Hirashima, Natsuko Suzuki, Ema Aoki, Taito Oshima, Mitsuru Hosoya, Masahiro Fujita, Toshiyuki Hayashi et al. · 2021 · Journal of Diabetes Investigation
66. Treatment of dyslipidemia in diabetes: recent advances and remaining questions
    Chait, Alan, Goldberg, Ira · 2017 · Current Diabetes Reports
67. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
    Vesa M. Olkkonen, Juha P. Sinisalo, Matti Jauhiainen · 2018 · Atherosclerosis
68. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials
    Federica Fogacci, Giuseppe Danilo Norata, Peter Paul Toth, Marcello Arca, Arrigo F.G. Cicero · 2020 · Current Atherosclerosis Reports
69. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia
    Ioanna Gouni‐Berthold · 2017 · Atherosclerosis Supplements
70. The Evolving Story of Triglycerides and Coronary Heart Disease Risk
    Ann Marie Návar · 2019 · JAMA
71. Strategies to Overcome Residual Risk During Statins Era
    Kyoung Im Cho, Jongwook Yu, Toshio Hayashi, Seung Hwan Han, Kwang Kon Koh · 2019 · Circulation Journal
72. Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
    Haizhao Yan, Manabu Niimi, Fumikazu Matsuhisa, Huanjin Zhou, Shuji Kitajima, Yajie Chen, Chuan Wang, Xiawen Yang, Jian Qiang Yao, Dongshan Yang et al. · 2020 · Arteriosclerosis Thrombosis and Vascular Biology
73. Advances in nanobased platforms for cardiovascular diseases: Early diagnosis, imaging, treatment, and tissue engineering
    Laleh Shariati, Yasaman Esmaeili, Ilnaz Rahimmanesh, Shahrzad Babolmorad, Ghazal Ziaei, Anwarul Hasan, Maryam Boshtam, Pooyan Makvandi · 2023 · Environmental Research
74. Gene-targeting pharmaceuticals for single-gene disorders
    Arthur L. Beaudet, Linyan Meng · 2015 · Human Molecular Genetics
75. Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study)
    Márcio Sommer Bittencourt, Raul Dias Santos, Henrique Lane Staniak, Rodolfo Sharovsky, Rao Kondapally, Antonio J. Vallejo‐Vaz, Kausik Kumar Ray, Isabela M. Benseñor, Paulo A. Lotufo · 2017 · The American Journal of Cardiology
76. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia
    Nick S. Nurmohamed, Geesje M. Dallinga‐Thie, Erik S.G. Stroes · 2020 · Expert Review of Cardiovascular Therapy
77. Downregulation of NK cell activities in Apolipoprotein C-III-induced hyperlipidemia resulting from lipid-induced metabolic reprogramming and crosstalk with lipid-laden dendritic cells
    Xiangyu Hu, Xiaoqin Jia, Cong Xu, Yingying Wei, Zhengbing Wang, Chaojie Liu, Qiang You, Guotao Lu, Weijuan Gong · 2021 · Metabolism
78. Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials
    Ilenia Lorenza Calcaterra, Roberta Lupoli, Alessandro Di Minno, Matteo Nicola Dario Di Minno · 2022 · European Journal of Clinical Investigation
79. Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
    Virginie Baylot, Thi Khanh Le, David Taïeb, Palma Rocchi, Laurence Colleaux · 2024 · Communications Biology
80. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups
    Shiwali Goyal, Yosuke Tanigawa, Weihua Zhang, Jin Fang Chai, Marcio Almeida, Xueling Sim, Megan R. Lerner, Juliane Chainakul, Jonathan Garcia Ramiu, Chanel Seraphin et al. · 2021 · Lipids in Health and Disease
81. Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies
    Waqas A. Malick, Ori Waksman, Ron Do, Wolfgang Köenig, Aruna D. Pradhan, Erik S.G. Stroes, Robert S. Rosenson · 2023 · Journal of the American College of Cardiology
82. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
    Brian Tomlinson, Qianyan Wu, Yi-ming Zhong, Yanhong Li · 2024 · Journal of Lipid and Atherosclerosis
83. Targeting angiotensinogen with RNA-based therapeutics
    Liwei Ren, Katrina M. Mirabito Colafella, Dominique M. Bovée, Estrellita Uijl, A.H. Jan Danser · 2019 · Current Opinion in Nephrology & Hypertension
84. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
    Laurens F. Reeskamp, Tycho R. Tromp, Erik S.G. Stroes · 2020 · Current Opinion in Lipidology
85. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies
    Israa Dib, Alia Khalil, Racha Chouaib, Yolla El-Makhour, Hiba Noureddine · 2021 · Molecular Biology Reports
86. New Drugs for Atherosclerosis
    Caroline Suzanne Bruikman, Robert M. Stoekenbroek, G. Kees Hovingh, John J.P. Kastelein · 2016 · Canadian Journal of Cardiology
87. APOC3 siRNA and ASO therapy for dyslipidemia
    Chebli, Jasmine, Larouche, Miriam, Gaudet, Daniel · 2024 · Current Opinion in Endocrinology, Diabetes & Obesity
88. Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK Early Access to Medicines Scheme (EAMS)
    Jones, Alan, Peers, Katherine, Wierzbicki, Anthony S., Ramachandran, Radha, Mansfield, Michael, Dawson, Charlotte, Ochoa-Ferraro, Antonio, Soran, Handrean, Jenkinson, Fiona, McDowell, Ian et al. · 2023 · Atherosclerosis
89. Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
    Jeffrey Alfonsi, Robert Alexander Hegele, Steven E. Gryn · 2016 · Current Atherosclerosis Reports
90. Dyslipidemias in clinical practice
    Manuel Castro Cabezas, Benjamin Burggraaf, Boudewijn Klop · 2018 · Clinica Chimica Acta
91. Targeting ApoC-III to Reduce Coronary Disease Risk
    Sumeet A. Khetarpal, Arman Qamar, John S. Millar, Daniel James Rader · 2016 · Current Atherosclerosis Reports
92. Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency
    Takeshi Okada, Tohru Ohama, Kazuaki Takafuji, Kotaro Kanno, Hibiki Matsuda, Masami Sairyo, Yinghong Zhu, Ayami Saga, Takuya Kobayashi, Daisaku Masuda et al. · 2019 · Journal of clinical lipidology
93. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors
    Natalie C. Kegulian, Bastian Ramms, Steven B. Horton, Olgica Trenchevska, Dobrin Nedelkov, Mark J. Graham, Richard G. Lee, Jeffrey D. Esko, Hussein N. Yassine, Philip L.S.M. Gordts · 2019 · Arteriosclerosis Thrombosis and Vascular Biology
94. Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
    Takahito Doi, Anne Langsted, Børge Grønne Nordestgaard · 2023 · Journal of Atherosclerosis and Thrombosis
95. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
    Katrina L. Ellis, Amanda J. Hooper, John R. Burnett, Gerald Francis Watts · 2016 · Nature Reviews Endocrinology
96. Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk
    Sarah A. Aroner, Ming Yang, Junlong Li, Jeremy D. Furtado, Frank M. Sacks, Anne Marie Tjønneland, Kim Overvad, Tianxi Cai, Majken K. Jensen · 2017 · American Journal of Epidemiology
97. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
    Kolovou, Genovefa, Kolovou, Vana, Katsiki, Niki · 2022 · Journal of Clinical Medicine
98. Therapeutic targets of triglyceride metabolism as informed by human genetics
    Bauer, Robert C., Khetarpal, Sumeet A., Hand, Nicholas J., Rader, Daniel J. · 2016 · Trends in Molecular Medicine
99. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
    Anthony S. Wierzbicki, Adie Viljoen · 2016 · Expert Opinion on Biological Therapy
100. Triglycerides and Open Angle Glaucoma – A Meta-analysis with meta-regression
     Laura Pertl, Georg Mossböck, Andreas Wedrich, Martin Weger, Oliver Königsbrügge, Günther Silbernagel, Florian Posch · 2017 · Scientific Reports